TCS Launches ADD AgentHub to Scale Agentic AI Platform Across Pharma Drug Development

TCS Introduces Enterprise AI Platform for Pharmaceutical R&D

Tata Consultancy Services has launched TCS ADD AgentHub, an agentic AI platform built to address trust, governance and scalability challenges pharmaceutical companies face when deploying AI across drug development workflows1

1

2

2

. The enterprise-ready AI platform enables pharma companies to deploy role-based AI agents across clinical trials and pharmacovigilance services while maintaining regulatory and audit requirements in highly regulated environments3

3

.

Pharmaceutical companies operate under increasing regulatory expectations, growing data volumes, and fragmented systems that add complexity across the R&D value chain1

1

. TCS ADD AgentHub provides a structured framework where AI agents operate with defined oversight, clear roles, and built-in auditability2

2

. Companies can custom build their AI agent hub and deploy them across clinical workflows with rapid integration and minimal implementation effort3

3

.

Measurable Efficiency Gains Across Clinical Operations

Solutions powered by the agentic AI platform have demonstrated up to 40% efficiency gains in clinical data management activities, up to 30% reduction in clinical study build effort through metadata-driven automation, and up to 30% cost savings in end-to-end safety case processing1

1

2

2

. AI-powered safety agents reduce quality control effort by as much as 50%, helping organizations improve productivity across critical R&D processes3

3

.

The platform supports workflows across clinical development and pharmacovigilance through AI workers handling ICSR intake, data entry, coding, review, and literature analysis2

2

. Additional capabilities include study design, protocol digitization, clinical data review, SDTM transformation, and medical monitoring assistance1

1

. AI agents in pharmaceutical R&D handle repetitive tasks such as data extraction and document review, while human teams retain responsibility for governance and final decision-making4

4

.

Human + AI Operating Model Maintains Governance

Built on the TCS ADD agentic AI architecture, the platform enables pharma companies to deploy a Human + AI Operating Model in which AI agents are embedded into enterprise workflows2

2

3

3

. Humans retain responsibility for governing and decision-making, ensuring regulatory compliance and patient safety remain under expert oversight4

4

.

Debashis Ghosh, President of Lifesciences and Healthcare at TCS, stated that TCS ADD AgentHub "will enable our customers to accelerate drug development using agentic AI at scale. It enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment"1

1

. He added that TCS' strategy moves toward autonomous enterprise functions where AI agentic workforce operates alongside humans driving innovation in drug development and improving patient safety2

2

.

Progressive Deployment Across Pharma R&D

With an evolving catalogue of AI agents suited to specific needs, companies can deploy them progressively based on requirements and landscape3

3

. The platform allows rapid and streamlined integration, accelerating adoption while maintaining regulatory compliance across AI-driven drug development processes1

1

. By standardizing how AI agents are deployed, the platform helps organizations improve productivity and focus scientific teams on higher-value work2

2

.

TCS aspires to become the world's largest AI-led technology services company through its comprehensive AI-first culture3

3

. By leveraging the proprietary cognitive intelligence of the TCS ADD suite, the company enables tangible, predictive, and secure digital ecosystems for customers navigating governance and scalability challenges in clinical trials and pharmacovigilance1

1

.